
JAMA Oncology Author Interviews
0 FOLLOWERS
Interviews with authors of articles from JAMA Oncology. JAMA Oncology is the definitive journal for scientists, clinicians, and trainees in the field of oncology worldwide. It aims to effectively convey the findings of important clinical research, major scientific breakthroughs, actionable discoveries, and state-of-the-art treatment pathways to the oncology community.
JAMA Oncology Author Interviews
2w ago
Interview with Jennifer M. Yeh, PhD, and Lisa R. Diller, MD, authors of Accelerated Aging in Survivors of Childhood Cancer—Early Onset and Excess Risk of Chronic Conditions. Hosted by Vivek Subbiah, MD.
Related Content:
Accelerated Aging in Survivors of Childhood Cancer—Early Onset and Excess Risk of Chronic Conditions
On Accelerated Aging—A Phenomenon in Survivors of Childhood Cancer ..read more
JAMA Oncology Author Interviews
1M ago
Interview with Anand P. Jillella, MD, author of Academic-Community Partnership and Deaths in Promyelocytic Leukemia: The Nonrandomized ECOG-ACRIN EA9131 Trial. Hosted by Vivek Subbiah, MD.
Related Content:
Academic Community Partnership in Acute Promyelocytic Leukemia and Early Mortality ..read more
JAMA Oncology Author Interviews
2M ago
Interview with Michael A. Postow, MD, author of Intracranial Outcomes of Ipilimumab and Nivolumab in Melanoma Brain Metastases After Progression on Anti–PD-1 Therapy. Hosted by Vivek Subbiah, MD.
Related Content:
Intracranial Outcomes of Ipilimumab and Nivolumab in Melanoma Brain Metastases After Progression on Anti–PD-1 Therapy ..read more
JAMA Oncology Author Interviews
4M ago
Interview with Katrina A. B. Goddard, PhD, author of Estimation of Cancer Deaths Averted From Prevention, Screening, and Treatment Efforts, 1975-2020. Hosted by Vivek Subbiah, MD.
Related Content:
Estimation of Cancer Deaths Averted From Prevention, Screening, and Treatment Efforts, 1975-2020 ..read more
JAMA Oncology Author Interviews
4M ago
Interview with Hagop Kantarjian, MD, author of Olverembatinib After Failure of Tyrosine Kinase Inhibitors, Including Ponatinib or Asciminib: A Phase 1b Randomized Clinical Trial. Hosted by Vivek Subbiah, MD.
Related Content:
Olverembatinib After Failure of Tyrosine Kinase Inhibitors, Including Ponatinib or Asciminib ..read more
JAMA Oncology Author Interviews
5M ago
Interview with Maria E. Cabanillas, MD, author of Anti–Programmed Death Ligand 1 Plus Targeted Therapy in Anaplastic Thyroid Carcinoma: A Nonrandomized Clinical Trial. Hosted by Vivek Subbiah, MD.
Related Content:
Anti–Programmed Death Ligand 1 Plus Targeted Therapy in Anaplastic Thyroid Carcinoma ..read more
JAMA Oncology Author Interviews
6M ago
Interview with Roni Shouval, MD, PhD, author of T-Cell Malignant Neoplasms After Chimeric Antigen Receptor T-Cell Therapy. Hosted by Vivek Subbiah, MD.
Related Content:
T-Cell Malignant Neoplasms After Chimeric Antigen Receptor T-Cell Therapy ..read more
JAMA Oncology Author Interviews
7M ago
Interview with Eileen M. O’Reilly, MD, author of Lynch Syndrome and Somatic Mismatch Repair Variants in Pancreas Cancer. Hosted by Vivek Subbiah, MD.
Related Content:
Lynch Syndrome and Somatic Mismatch Repair Variants in Pancreas Cancer ..read more
JAMA Oncology Author Interviews
7M ago
Interview with Michelle Rengarajan, MD, PhD, author of Identification of Immune Checkpoint Inhibitor–Induced Diabetes. Hosted by Vivek Subbiah, MD.
Related Content:
Identification of Immune Checkpoint Inhibitor–Induced Diabetes ..read more
JAMA Oncology Author Interviews
9M ago
Interview with Lee W. Jones, PhD, author of Neoadjuvant Exercise Therapy in Prostate Cancer: A Phase 1, Decentralized Nonrandomized Controlled Trial. Hosted by Vivek Subbiah, MD. Related Content:
Neoadjuvant Exercise Therapy in Prostate Cancer ..read more